{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:21:01Z","timestamp":1788445261325,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006668","name":"Fund for Scientific and Technological Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006668","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012478","name":"National University of Cordoba Secretariat of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bmcl.2026.130744","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:46:30Z","timestamp":1785307590000},"page":"130744","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Toward targeted covalent inhibition of Cruzipain for the treatment of Chagas disease"],"prefix":"10.1016","volume":"141","author":[{"given":"Juan Ignacio","family":"Estrada Canepa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio Rom\u00e1n","family":"Ribone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agustina","family":"Grich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Pablo","family":"Cerutti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7891-7834","authenticated-orcid":false,"given":"Mario Alfredo","family":"Quevedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b1","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.3390\/ijms25073840","article-title":"Chagas disease: a silent threat for dogs and humans","volume":"25","author":"Dur\u00e3es-Oliveira","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130744_b2","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1007\/s11886-024-02113-7","article-title":"Chagas disease: epidemiology, diagnosis, and treatment","volume":"26","author":"Swett","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.bmcl.2026.130744_b3","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2174\/9789815324785125010006","article-title":"Chagas diseases: State of the art and new perspectives","author":"Renzi","year":"2025","journal-title":"Adv Med Chem Neglected Trop Dis Relat Infect Dis"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b4","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3390\/pathogens14040337","article-title":"An overview of trypanosoma cruzi biology through the lens of proteomics: A review","volume":"14","author":"Telleria","year":"2025","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b5","doi-asserted-by":"crossref","first-page":"488","DOI":"10.3390\/life14040488","article-title":"The end justifies the means: Chagas disease from a perspective of the host\u2013Trypanosoma cruzi interaction","volume":"14","author":"Rossi","year":"2024","journal-title":"Life"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b6","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1021\/acsinfecdis.2c00123","article-title":"An updated view of the trypanosoma cruzi life cycle: Intervention points for an effective treatment","volume":"8","author":"Mart\u00edn-Escolano","year":"2022","journal-title":"ACS Infect Dis"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130744_b7","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.3390\/life13122339","article-title":"Fifteen years after the definition of trypanosoma cruzi DTUs: what have we learned?","volume":"13","author":"Zingales","year":"2023","journal-title":"Life"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2174\/2211352521666230823122601","article-title":"Current therapeutic strategies for chagas disease","volume":"22","author":"Narwal","year":"2024","journal-title":"Anti-Infective Agents"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b9","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1080\/13543784.2024.2349289","article-title":"Drugs in preclinical and early clinical development for the treatment of Chaga\u015b s disease: the current status","volume":"33","author":"Torchelsen","year":"2024","journal-title":"Expert Opin Investig Drugs"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130744_b10","article-title":"Improving translational paradigms in drug discovery and development","volume":"1","author":"Williams","year":"2021","journal-title":"Curr Protoc"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b11","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202200434","article-title":"Investigating the lack of translation from cruzain inhibition to trypanosoma cruzi activity with machine learning and chemical space analyses","volume":"18","author":"Lameiro","year":"2023","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130744_b12","article-title":"The translational challenge in chagas disease drug development","volume":"117","author":"Kratz","year":"2022","journal-title":"Memorias Do Inst Oswaldo Cruz"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b13","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbapap.2020.140577","article-title":"Update on relevant trypanosome peptidases: Validated targets and future challenges","volume":"1869","author":"Alvarez","year":"2021","journal-title":"Biochim Biophys Acta (BBA)-Proteins Proteom"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130744_b14","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.2174\/092986709788802971","article-title":"Cruzipain, the major cysteine protease of trypanosoma cruzi: a sulfated glycoprotein antigen as relevant candidate for vaccine development and drug target. a review","volume":"16","author":"Duschak","year":"2009","journal-title":"Curr Med Chem"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130744_b15","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/14728222.2023.2264512","article-title":"Molecular targets for chagas disease: Validation, challenges and lead compounds for widely exploited targets","volume":"27","author":"Laureano de Souza","year":"2023","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b16","doi-asserted-by":"crossref","first-page":"18231","DOI":"10.1038\/s41598-021-97490-2","article-title":"The gene repertoire of the main cysteine protease of trypanosoma cruzi, cruzipain, reveals four sub-types with distinct active sites","volume":"11","author":"Santos","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.bmcl.2026.130744_b17","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2024.106458","article-title":"Chagasin from trypanosoma cruzi as a molecular scaffold to express epitopes of TSA-1 as soluble recombinant chimeras","volume":"218","author":"C\u00e1rdenas-Guerra","year":"2024","journal-title":"Protein Express Purif"},{"key":"10.1016\/j.bmcl.2026.130744_b18","doi-asserted-by":"crossref","DOI":"10.1016\/j.micres.2022.127061","article-title":"Endogenous cysteine protease inhibitors in upmost pathogenic parasitic protozoa","volume":"261","author":"Roy","year":"2022","journal-title":"Microbiol Res"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130744_b19","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1039\/C9CS00720B","article-title":"Advances in covalent kinase inhibitors","volume":"49","author":"Abdeldayem","year":"2020","journal-title":"Chem Soc Rev"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b20","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1021\/acs.jmedchem.4c02661","article-title":"A medicinal chemistry perspective on FDA-approved small molecule drugs with a covalent mechanism of action","volume":"68","author":"Dalton","year":"2025","journal-title":"J Med Chem"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/ph17020206","article-title":"Targeted covalent inhibitors in drug discovery, chemical biology and beyond","volume":"17","author":"Serafim","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130744_b22","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.1021\/acs.jmedchem.1c02134","article-title":"The ascension of targeted covalent inhibitors","volume":"65","author":"Singh","year":"2022","journal-title":"J Med Chem"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130744_b23","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1039\/C7CS00220C","article-title":"Structure-based design of targeted covalent inhibitors","volume":"47","author":"Lonsdale","year":"2018","journal-title":"Chem Soc Rev"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b24","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3390\/ph16071028","article-title":"Covalent inhibitors for neglected diseases: An exploration of novel therapeutic options","volume":"16","author":"Alves","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130744_b25","doi-asserted-by":"crossref","first-page":"7668","DOI":"10.1021\/acs.jmedchem.3c01825","article-title":"Emerging and re-emerging warheads for targeted covalent inhibitors: an update","volume":"67","author":"Hillebrand","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b26","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2024.117902","article-title":"Recent advances in the design of small molecular drugs with acrylamides covalent warheads","volume":"112","author":"Liang","year":"2024","journal-title":"Bioorganic Med Chem"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b27","doi-asserted-by":"crossref","first-page":"243","DOI":"10.2174\/1385272827666230418100932","article-title":"Cruzain inhibitors: State-of-art of novel synthetic strategies","volume":"27","author":"Bezerra Morais","year":"2023","journal-title":"Curr Org Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b28","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.ejmech.2018.08.079","article-title":"Synthesis and structure-activity relationship studies of cruzain and rhodesain inhibitors","volume":"157","author":"Rocha","year":"2018","journal-title":"Eur J Med Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b29","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1016\/j.drudis.2015.02.004","article-title":"Cruzain inhibitors: efforts made, current leads and a structural outlook of new hits","volume":"20","author":"Martinez-Mayorga","year":"2015","journal-title":"Drug Discov Today"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130744_b30","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1016\/S0021-9258(18)42533-1","article-title":"The sequence, organization, and expression of the major cysteine protease (cruzain) from trypanosoma cruzi","volume":"267","author":"Eakin","year":"1992","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b31","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.3390\/cells9071679","article-title":"The ins and outs of cathepsins: physiological function and role in disease management","volume":"9","author":"Yadati","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.bmcl.2026.130744_b32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115498","article-title":"Structure-based discovery of novel cruzain inhibitors with distinct trypanocidal activity profiles","volume":"257","author":"Santos","year":"2023","journal-title":"Eur J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b33","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1021\/acsmedchemlett.4c00631","article-title":"Thiosulfonate-based targeted covalent cruzipain inhibitors with enhanced bioactivity translation for antichagasic therapy","volume":"16","author":"Cerutti","year":"2025","journal-title":"ACS Med Chem Lett"},{"issue":"18","key":"10.1016\/j.bmcl.2026.130744_b34","first-page":"19115","article-title":"Unraveling common patterns and differences among cruzipains through molecular dynamics simulations and structural analyses","volume":"10","author":"Santos","year":"2025","journal-title":"ACS Omega"},{"issue":"23","key":"10.1016\/j.bmcl.2026.130744_b35","doi-asserted-by":"crossref","first-page":"10497","DOI":"10.1021\/acs.jmedchem.9b00683","article-title":"Can cysteine protease cross-class inhibitors achieve selectivity?","volume":"62","author":"Cianni","year":"2019","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b36","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/cbdd.14257","article-title":"A comprehensive review on potential candidates for the treatment of chagas disease","volume":"102","author":"Pathak","year":"2023","journal-title":"Chem Biology Drug Des"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b37","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/acs.jmedchem.3c01502","article-title":"Pitfalls and considerations in determining the potency and mutant selectivity of covalent epidermal growth factor receptor inhibitors: Miniperspective","volume":"67","author":"Hoyt","year":"2023","journal-title":"J Med Chem"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130744_b38","doi-asserted-by":"crossref","first-page":"14693","DOI":"10.1021\/acs.jmedchem.4c01721","article-title":"Demystifying functional parameters for irreversible enzyme inhibitors","volume":"67","author":"Heppner","year":"2024","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b39","article-title":"Improving in vitro screening compounds anti-trypanosoma cruzi by GFP-expressing parasites","volume":"119","author":"Delvoss","year":"2024","journal-title":"Mem\u00f3rias Inst Oswaldo Cruz"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b40","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1039\/D4MD00707G","article-title":"A practical guide for the assay-dependent characterisation of irreversible inhibitors","volume":"16","author":"Mader","year":"2025","journal-title":"RSC Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13321-025-00963-z","article-title":"Fifteen years of ChEMBL and its role in cheminformatics and drug discovery","volume":"17","author":"Zdrazil","year":"2025","journal-title":"J Cheminformatics"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b42","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/acsmedchemlett.4c00460","article-title":"Discovery of a potent triazole-based reversible targeted covalent inhibitor of cruzipain","volume":"16","author":"Cerutti","year":"2024","journal-title":"ACS Med Chem Lett"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130744_b43","doi-asserted-by":"crossref","first-page":"4224","DOI":"10.3390\/molecules29174224","article-title":"Structure-aided computational design of triazole-based targeted covalent inhibitors of cruzipain","volume":"29","author":"Cerutti","year":"2024","journal-title":"Molecules"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130744_b44","doi-asserted-by":"crossref","first-page":"12579","DOI":"10.1021\/acs.jcim.5c01849","article-title":"Structure-based discovery of non-covalent triazole-based cruzipain inhibitors with improved bioactivity translation","volume":"65","author":"Cerutti","year":"2025","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b45","doi-asserted-by":"crossref","first-page":"227","DOI":"10.3390\/pharmaceutics16020227","article-title":"The potential use of peptides in the fight against chagas disease and leishmaniasis","volume":"16","author":"Berhe","year":"2024","journal-title":"Pharmaceutics"},{"issue":"44","key":"10.1016\/j.bmcl.2026.130744_b46","doi-asserted-by":"crossref","first-page":"60104","DOI":"10.1021\/acsami.5c18100","article-title":"Peptide-based targeted covalent inhibitors","volume":"17","author":"Cao","year":"2025","journal-title":"ACS Appl Mater Interfaces"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b47","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007755","article-title":"Mapping the S1 and S1\u2019subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents","volume":"14","author":"Cianni","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b48","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003916","article-title":"Molecular design, synthesis and trypanocidal activity of dipeptidyl nitriles as cruzain inhibitors","volume":"9","author":"Avelar","year":"2015","journal-title":"PLOS Neglected Trop Dis"},{"issue":"30","key":"10.1016\/j.bmcl.2026.130744_b49","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/0113816128267517231010061552","article-title":"Pharmacokinetic limitations to overcome and enable K777 as a potential drug against chagas disease","volume":"29","author":"De Souza","year":"2023","journal-title":"Curr Pharm Des"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130744_b50","doi-asserted-by":"crossref","first-page":"5160","DOI":"10.1128\/AAC.49.12.5160-5161.2005","article-title":"A cysteine protease inhibitor protects dogs from cardiac damage during infection by Trypanosoma cruzi","volume":"49","author":"Barr","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"issue":"38","key":"10.1016\/j.bmcl.2026.130744_b51","doi-asserted-by":"crossref","first-page":"25697","DOI":"10.1074\/jbc.M109.014340","article-title":"Vinyl sulfones as antiparasitic agents and a structural basis for drug design","volume":"284","author":"Kerr","year":"2009","journal-title":"J Biol Chem"},{"issue":"30","key":"10.1016\/j.bmcl.2026.130744_b52","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.2174\/0113816128267517231010061552","article-title":"Pharmacokinetic limitations to overcome and enable K777 as a potential drug against chagas disease","volume":"29","author":"De Souza","year":"2023","journal-title":"Curr Pharm Des"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b53","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1021\/acschembio.0c00875","article-title":"A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 infection of human and monkey cells","volume":"16","author":"Mellott","year":"2021","journal-title":"ACS Chem Biology"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b54","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1021\/acsmedchemlett.5b00336","article-title":"Synthesis and evaluation of oxyguanidine analogues of the cysteine protease inhibitor WRR-483 against cruzain","volume":"7","author":"Jones","year":"2016","journal-title":"ACS Med Chem Lett"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130744_b55","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0000825","article-title":"In vitro and in vivo studies of the trypanocidal properties of WRR-483 against Trypanosoma cruzi","volume":"4","author":"Chen","year":"2010","journal-title":"PLoS Neglected Trop Dis"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0007755","article-title":"Mapping the S1 and S1\u2019subsites of cysteine proteases with new dipeptidyl nitrile inhibitors as trypanocidal agents","volume":"14","author":"Cianni","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"issue":"20","key":"10.1016\/j.bmcl.2026.130744_b57","doi-asserted-by":"crossref","first-page":"9026","DOI":"10.1021\/acs.jmedchem.9b00294","article-title":"Design of gallinamide A analogs as potent inhibitors of the cysteine proteases human cathepsin L and trypanosoma cruzi cruzain","volume":"62","author":"Boudreau","year":"2019","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130744_b58","doi-asserted-by":"crossref","first-page":"4255","DOI":"10.1021\/acs.jmedchem.1c02063","article-title":"Intramolecular interactions enhance the potency of gallinamide A analogues against Trypanosoma cruzi","volume":"65","author":"Barbosa Da Silva","year":"2022","journal-title":"J Med Chem"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130744_b59","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115743","article-title":"Crystal structure of leishmania mexicana cysteine protease B in complex with a high-affinity azadipeptide nitrile inhibitor","volume":"28","author":"Ribeiro","year":"2020","journal-title":"Bioorganic Med Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b60","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/cbdd.12055","article-title":"The future of peptide-based drugs","volume":"81","author":"Craik","year":"2013","journal-title":"Chem Biology Drug Des"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b61","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/17425247.2022.2051476","article-title":"Progress and limitations of oral peptide delivery as a potentially transformative therapy","volume":"19","author":"Tran","year":"2022","journal-title":"Expert Opin Drug Deliv"},{"issue":"20","key":"10.1016\/j.bmcl.2026.130744_b62","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1002\/ejoc.201901838","article-title":"The challenge of conformational isomerism in cyclic peptoids","volume":"2020","author":"De Riccardis","year":"2020","journal-title":"Eur J Org Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b63","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116211","article-title":"Nitrile-based peptoids as cysteine protease inhibitors","volume":"41","author":"Alves","year":"2021","journal-title":"Bioorganic Med Chem"},{"issue":"20","key":"10.1016\/j.bmcl.2026.130744_b64","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1021\/ja710254m","article-title":"Identification of a new class of nonpeptidic inhibitors of cruzain","volume":"130","author":"Brak","year":"2008","journal-title":"J Am Chem Soc"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b65","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/jm901633v","article-title":"Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for chagas disease chemotherapy","volume":"53","author":"Brak","year":"2010","journal-title":"J Med Chem"},{"issue":"21","key":"10.1016\/j.bmcl.2026.130744_b66","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1016\/j.bmcl.2015.06.066","article-title":"Tetrafluorophenoxymethyl ketone cruzain inhibitors with improved pharmacokinetic properties as therapeutic leads for chagas\u2019 disease","volume":"25","author":"Neitz","year":"2015","journal-title":"Bioorganic Med Chem Lett"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130744_b67","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2023.103799","article-title":"The expanding repertoire of covalent warheads for drug discovery","volume":"28","author":"Mehta","year":"2023","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130744_b68","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1016\/j.bmc.2019.04.002","article-title":"Characterising covalent warhead reactivity","volume":"27","author":"Martin","year":"2019","journal-title":"Bioorganic Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130744_b69","doi-asserted-by":"crossref","first-page":"3326","DOI":"10.1021\/acs.biochem.8b00315","article-title":"The taxonomy of covalent inhibitors","volume":"57","author":"Tuley","year":"2018","journal-title":"Biochemistry"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b70","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/17568919.2025.2453407","article-title":"Key advances in the development of reversible covalent inhibitors","volume":"17","author":"Faridoon","year":"2025","journal-title":"Futur Med Chem"},{"issue":"12","key":"10.1016\/j.bmcl.2026.130744_b71","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1007\/s00726-023-03286-1","article-title":"Covalent-reversible peptide-based protease inhibitors. Design, synthesis, and clinical success stories","volume":"55","author":"Feral","year":"2023","journal-title":"Amino Acids"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b72","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1039\/D2MD00204C","article-title":"Nitriles: an attractive approach to the development of covalent inhibitors","volume":"14","author":"Bonatto","year":"2023","journal-title":"RSC Med Chem"},{"issue":"24","key":"10.1016\/j.bmcl.2026.130744_b73","doi-asserted-by":"crossref","first-page":"7444","DOI":"10.1016\/j.bmcl.2010.10.015","article-title":"Identification of potent and reversible cruzipain inhibitors for the treatment of Chagas disease","volume":"20","author":"Beaulieu","year":"2010","journal-title":"Bioorganic Med Chem Lett"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b74","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1021\/jm901069a","article-title":"Identification and optimization of inhibitors of Trypanosomal cysteine proteases: Cruzain, rhodesain, and TbCatB","volume":"53","author":"Mott","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b75","article-title":"Review of peptidomimetic vinyl sulfones targeting cysteine proteases and proteasomes","author":"Ahmadi","year":"2025","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmcl.2026.130744_b76","doi-asserted-by":"crossref","DOI":"10.37349\/eds.2026.1008147","article-title":"Vinyl sulfones: selective and tunable covalent warheads against challenging enzyme targets","volume":"4","author":"Viola","year":"2026","journal-title":"Explor Drug Sci"},{"issue":"22","key":"10.1016\/j.bmcl.2026.130744_b77","doi-asserted-by":"crossref","first-page":"5860","DOI":"10.1016\/j.bmcl.2008.06.012","article-title":"Synthesis of macrocyclic trypanosomal cysteine protease inhibitors","volume":"18","author":"Chen","year":"2008","journal-title":"Bioorganic Med Chem Lett"},{"issue":"7","key":"10.1016\/j.bmcl.2026.130744_b78","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health","volume":"35","author":"O\u2019Brien","year":"2005","journal-title":"Crit Rev Toxicol"},{"issue":"15","key":"10.1016\/j.bmcl.2026.130744_b79","doi-asserted-by":"crossref","first-page":"11267","DOI":"10.1021\/acs.jmedchem.1c00628","article-title":"Self-masked aldehyde inhibitors: a novel strategy for inhibiting cysteine proteases","volume":"64","author":"Li","year":"2021","journal-title":"J Med Chem"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130744_b80","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1021\/acs.jcim.2c01566","article-title":"Experimental and computational study of aryl-thiosemicarbazones inhibiting cruzain reveals reversible inhibition and a stepwise mechanism","volume":"63","author":"Martins","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130744_b81","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.3390\/molecules30081788","article-title":"Recent progress in thiazole, thiosemicarbazone, and semicarbazone derivatives as antiparasitic agents against trypanosomatids and plasmodium spp","volume":"30","author":"Souza Tada da Cunha","year":"2025","journal-title":"Molecules"},{"issue":"21","key":"10.1016\/j.bmcl.2026.130744_b82","doi-asserted-by":"crossref","first-page":"19038","DOI":"10.1021\/acs.jmedchem.4c01535","article-title":"Synthesis and biological evaluation of new chalcogen semicarbazone (S, Se) and their azole derivatives against chagas disease","volume":"67","author":"Rubio-Hernandez","year":"2024","journal-title":"J Med Chem"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b83","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1021\/acs.jcim.4c01591","article-title":"Computational methods for predicting chemical reactivity of covalent compounds","volume":"65","author":"Zhang","year":"2025","journal-title":"J Chem Inf Model"},{"issue":"45","key":"10.1016\/j.bmcl.2026.130744_b84","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1021\/acs.jpcb.3c04710","article-title":"Landscape of in silico tools for modeling covalent modification of proteins: a review on computational covalent drug discovery","volume":"127","author":"Hasan","year":"2023","journal-title":"J Phys Chem B"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b85","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1021\/acs.accounts.5c00905","article-title":"Computational and AI-driven ecosystem for structure-based covalent drug discovery","volume":"59","author":"Li","year":"2026","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.bmcl.2026.130744_b86","article-title":"Computational approaches towards the discovery and optimisation of cruzain inhibitors","volume":"117","author":"Santos","year":"2022","journal-title":"Mem\u00f3rias Inst Oswaldo Cruz"},{"issue":"11","key":"10.1016\/j.bmcl.2026.130744_b87","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1080\/17460441.2025.2558161","article-title":"Exploiting PubChem and other public databases for virtual screening in 2025: what are the latest trends?","volume":"20","author":"Marb\u00e1n-Gonz\u00e1lez","year":"2025","journal-title":"Expert Opin Drug Discov"},{"issue":"4","key":"10.1016\/j.bmcl.2026.130744_b88","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1021\/acs.jcim.2c01253","article-title":"ZINC-22-A free multi-billion-scale database of tangible compounds for ligand discovery","volume":"63","author":"Tingle","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"5","key":"10.1016\/j.bmcl.2026.130744_b89","doi-asserted-by":"crossref","first-page":"662","DOI":"10.2174\/0929867326666191016114839","article-title":"In silico drug repositioning for Chagas disease","volume":"27","author":"Bellera","year":"2020","journal-title":"Curr Med Chem"},{"issue":"7893","key":"10.1016\/j.bmcl.2026.130744_b90","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1038\/s41586-021-04220-9","article-title":"Synthon-based ligand discovery in virtual libraries of over 11 billion compounds","volume":"601","author":"Sadybekov","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2026.130744_b91","series-title":"TidyScreen: A python package to manage large virtual screening campaigns","author":"Cerutti","year":"2025"},{"issue":"42","key":"10.1016\/j.bmcl.2026.130744_b92","doi-asserted-by":"crossref","first-page":"38961","DOI":"10.1021\/acsomega.3c03376","article-title":"Convergent QSAR models for the prediction of cruzain inhibitors","volume":"8","author":"Gon\u00e7alves","year":"2023","journal-title":"ACS Omega"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b93","article-title":"Accelerating covalent drug discovery: Recent advances in covalent docking tools","volume":"15","author":"Li","year":"2025","journal-title":"Wiley Interdiscip Rev: Comput Mol Sci"},{"key":"10.1016\/j.bmcl.2026.130744_b94","doi-asserted-by":"crossref","DOI":"10.3389\/fchem.2020.00246","article-title":"High-throughput docking using quantum mechanical scoring","volume":"8","author":"Cavasotto","year":"2020","journal-title":"Front Chem"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b95","doi-asserted-by":"crossref","first-page":"bbaf697","DOI":"10.1093\/bib\/bbaf697","article-title":"The covalent docking software landscape: features and applications in drug design","volume":"26","author":"Singh","year":"2025","journal-title":"Brief Bioinform"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b96","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1038\/s42004-025-01606-y","article-title":"Structure-based rational design of covalent probes","volume":"8","author":"Holcomb","year":"2025","journal-title":"Commun Chem"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b97","doi-asserted-by":"crossref","first-page":"12073","DOI":"10.1038\/s41598-017-12170-4","article-title":"Novel scaffolds for inhibition of cruzipain identified from high-throughput screening of anti-kinetoplastid chemical boxes","volume":"7","author":"Salas-Sarduy","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b98","doi-asserted-by":"crossref","first-page":"bbac559","DOI":"10.1093\/bib\/bbac559","article-title":"HCovDock: an efficient docking method for modeling covalent protein\u2013ligand interactions","volume":"24","author":"Wu","year":"2023","journal-title":"Brief Bioinform"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130744_b99","doi-asserted-by":"crossref","first-page":"5631","DOI":"10.1021\/acs.jcim.3c00832","article-title":"Reactive docking: A computational method for high-throughput virtual screenings of reactive species","volume":"63","author":"Bianco","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"10","key":"10.1016\/j.bmcl.2026.130744_b100","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70283","article-title":"Evaluating the protonation state of the catalytic Cys25 in cruzain cysteine protease: A target for Chagas disease","volume":"34","author":"da Costa","year":"2025","journal-title":"Prot Sci"},{"issue":"1\u20133","key":"10.1016\/j.bmcl.2026.130744_b101","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0010-4655(95)00042-E","article-title":"GROMACS: A message-passing parallel molecular dynamics implementation","volume":"91","author":"Berendsen","year":"1995","journal-title":"Comput Phys Comm"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b102","first-page":"198","article-title":"An overview of the amber biomolecular simulation package","volume":"3","author":"Salomon-Ferrer","year":"2013","journal-title":"Wiley Interdiscip Rev: Comput Mol Sci"},{"issue":"1","key":"10.1016\/j.bmcl.2026.130744_b103","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1021\/acs.jpcb.3c06662","article-title":"OpenMM 8: molecular dynamics simulation with machine learning potentials","volume":"128","author":"Eastman","year":"2023","journal-title":"J Phys Chem B"},{"key":"10.1016\/j.bmcl.2026.130744_b104","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/9783527840748.ch23","article-title":"Free energy calculations in covalent drug design","volume":"2","author":"Mihalovits","year":"2024","journal-title":"Comput Drug Discov: Methods Appl"},{"key":"10.1016\/j.bmcl.2026.130744_b105","series-title":"Thermodynamic drivers of covalent cruzain inhibition beyond enthalpy-entropy compensation","author":"Barbosa","year":"2025"},{"issue":"8","key":"10.1016\/j.bmcl.2026.130744_b106","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1021\/acs.jpcb.1c09424","article-title":"Assessing the performance of screening MM\/PBSA in protein\u2013ligand interactions","volume":"126","author":"Zhu","year":"2022","journal-title":"J Phys Chem B"},{"issue":"6","key":"10.1016\/j.bmcl.2026.130744_b107","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1021\/acsphyschemau.3c00033","article-title":"Modern alchemical free energy methods for drug discovery explained","volume":"3","author":"York","year":"2023","journal-title":"ACS Phys Chem Au"},{"key":"10.1016\/j.bmcl.2026.130744_b108","doi-asserted-by":"crossref","DOI":"10.1021\/acs.jcim.6c00089","article-title":"Large-scale collaborative assessment of binding free energy calculations for drug discovery using openfe","author":"Baumann","year":"2026","journal-title":"J Chem Inf Model"},{"issue":"33","key":"10.1016\/j.bmcl.2026.130744_b109","doi-asserted-by":"crossref","first-page":"8536","DOI":"10.1021\/acs.jpclett.5c01680","article-title":"Challenges and advances in the simulation of targeted covalent inhibitors using quantum computing","volume":"16","author":"Chaudhuri","year":"2025","journal-title":"J Phys Chem Lett"},{"issue":"17","key":"10.1016\/j.bmcl.2026.130744_b110","doi-asserted-by":"crossref","first-page":"4083","DOI":"10.1021\/acs.jcim.2c00466","article-title":"Assessment of reversibility for covalent cysteine protease inhibitors using quantum mechanics\/molecular mechanics free energy surfaces","volume":"62","author":"Dos Santos","year":"2022","journal-title":"J Chem Inf Model"},{"issue":"9","key":"10.1016\/j.bmcl.2026.130744_b111","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1002\/chem.201904513","article-title":"Quantum mechanics\/molecular mechanics studies of the mechanism of cysteine proteases inhibition by dipeptidyl nitroalkenes","volume":"26","author":"Arafet","year":"2020","journal-title":"Chem Eur J"},{"issue":"3","key":"10.1016\/j.bmcl.2026.130744_b112","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1021\/acs.jcim.9b01138","article-title":"Assessment of the cruzain cysteine protease reversible and irreversible covalent inhibition mechanism","volume":"60","author":"Silva","year":"2020","journal-title":"J Chem Inf Model"},{"issue":"2","key":"10.1016\/j.bmcl.2026.130744_b113","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202500630","article-title":"Machine learning-guided repositioning of a SARS-CoV-2-targeting molecular series as cruzain inhibitors","volume":"21","author":"Lameiro","year":"2026","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2026.130744_b114","doi-asserted-by":"crossref","DOI":"10.1021\/acsomega.5c08795","article-title":"TropMol-caipora: A cloud-based web tool to predict cruzain inhibitors by machine learning","author":"Doring","year":"2026","journal-title":"ACS Omega"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002118?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X26002118?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T14:09:26Z","timestamp":1788444566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X26002118"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":114,"alternative-id":["S0960894X26002118"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130744","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward targeted covalent inhibition of Cruzipain for the treatment of Chagas disease","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2026.130744","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130744"}}